Cannabidiol inhibits the hyperlocomotion induced by psychotomimetic drugs in mice

European Journal of Pharmacology

Volumn 512, Issue 2-3, 2005, Pages 199-205

  Moreira, Fabrício A ^a   Guimarães, Francisco S ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Antipsychotic; Cannabidiol; Cannabinoid; Catalepsy; Locomotion; Psychotomimetic

Indexed keywords

CANNABIDIOL; CANNABIS; CLOZAPINE; DEXAMPHETAMINE; DOPAMINE RECEPTOR STIMULATING AGENT; HALOPERIDOL; KETAMINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NEUROLEPTIC AGENT; PSYCHEDELIC AGENT;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CATALEPSY; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; EXTRAPYRAMIDAL SYMPTOM; FOREFOOT; FUNCTION TEST; LOCOMOTION; MALE; MEASUREMENT; MOUSE; NONHUMAN; PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL; TRANQUILIZING ACTIVITY;

EID: 17444393586     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2005.02.040     Document Type: Article

References (44)

1. T. Bisogno, L. Hanus, L. De Petrocelis, S. Tehilibon, D.E. Ponde, I. Brandi, A.S. Moriello, J.B. Davis, R. Mechoulam, and V. Di Marzo Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide Br. J. Pharmacol. 134 2001 845 852
2. E.A. Carlini, J.R. Leite, M. Tannhauser, and A.C. Berardi Cannabidiol and Cannabis sativa extract protect mice against convulsive agents J. Pharm. Pharmacol. 25 1973 664 665
3. A. Carlsson, N. Waters, S. Waters, and M. Calrsson Network interactions in schizophrenia-therapeutic implications Brain Res. Rev. 31 2000 342 349
4. D.E. Casey Motor and mental aspects of acute extrapyramidal side syndromes Acta Psychiatr. Scand. 89 1994 S14 S20
5. D.R. Compton, M.R. Johnson, L.S. Melvin, and B.R. Martin Pharmacological profile of a series of bicyclic cannabinoid analogs: classification as cannabimimetic agents J. Pharmacol. Exp. Ther. 260 1992 201 209
6. M.F. Egan, and D.R. Weinberger Neurobiology of schizophrenia Curr. Opin. Neurobiol. 7 1997 701 707
7. H.M. Emrich, F.M. Leweke, and U. Schneider Towards a cannabinoid hypothesis of schizophrenia: cognitive impairment due to dysregulation of the endogenous cannabinoid system Pharmacol. Biochem. Behav. 56 1997 803 807
8. E.A. Formukong, A.T. Evans, and F.J. Evans Inhibition of the cataleptic effect of tetrahydrocannabinol by other constituents of Cannabis sativa L. J. Pharm. Pharmacol. 40 1988 132 134
9. R. Freedman Schizophrenia N. Engl. J. Med. 349 2003 1738 1749
10. J. Gerlach New antipsychotics: classification, efficacy and adverse effects Schizophr. Bull. 17 1991 289 309
11. D.C. Goof, and J.T. Coyle The emerging role of glutamate in the pathophysiology and treatment of schizophrenia Am. J. Psychiatry 158 2001 1367 1377
12. F.S. Guimarães, T.M. Chiaretti, F.G. Graeff, and A.W. Zuardi Antianxiety effect of cannabidiol in the elevated plus-maze Psychopharmacology 100 1990 558 559
13. V.M.C. Guimarães, A.W. Zuardi, E.A. Del Bel, and F.S. Guimarães Cannabidiol increases Fos expression in the nucleus accumbens but not in the dorsal striatum Life Sci. 75 2004 633 638
14. D. Harris, and S.L. Batki Stimulant psychosis: symptom profile and acute clinical course Am. J. Addict. 9 2000 28 37
15. D.C. Hoffman, and H. Donovan Catalepsy as a rodent model for detecting antipsychotic drugs with extrapyramidal side effects Psychopharmacology 120 1995 128 133
16. C.A. Hunt, R.T. Jones, R.I. Herning, and J. Bachman Evidence that cannabidiol does not significantly alter the pharmacokinetics of tetrahydrocannabinol in man J. Pharmacokinet. Biopharm. 9 1981 245 260
17. M. Irifune, T. Shimizu, and M. Nomoto Ketamine-induced hyperlocomtion associated with alteration of presynaptic components of dopamine neurons in the nucleus accumbens of mice Pharmacol. Biochem. Behav. 40 1991 399 407
18. S.D. Iversen Is it possible to model psychotic states in animals J. Psychopharmacol. 4 1987 154 176
19. 9- tetrahydrocannabinol in man Eur. J. Pharmacol. 28 1974 172 177
20. C.D. Kilts The changing roles and targets for animal models of schizophrenia Biol. Psychiatry 50 2001 845 855
21. A.C. Lahti, M.A. Weiler, B.A. Tamara Michaelidis, A. Parwani, and C.A. Tamminga Effects of ketamine in normal and schizophrenic volunteers Neuropsychopharmacology 25 2001 455 467
22. M. Laruelle, A. Abi-Dargham, C.H. van Dyck, R. Gil, C.D. D́Souza, J. Erdos, E. McCance, W. Rosenblatt, C. Fingado, S.S. Zoghbi, R.M. Baldwin, J.P. Seibyl, J.H. Krystal, D.S. Charney, and R.B. Innis Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects Proc. Natl. Acad. Sci. 93 1996 9235 9240
23. B.K. Lipska, and D.R. Weinberger To model a psychiatric disorder in animals: schizophrenia as a reality test Neuropsychopharmacology 23 2000 223 239
24. R. Mechoulam Marihuana chemistry Science 168 1970 1159 1166
25. R. Mechoulam, and A. Shani Chemical basis of marihuana activity Science 169 1970 611 612
26. B. Moghadam Bringing order to the glutamate chaos in schizophrenia Neuron 40 2003 881 884
27. J.M. Monti Hypnotic-like effects of cannabidiol in the rat Psychopharmacology 55 1977 263 265
28. J.I. Morgan, and T. Curran Stimulus-transcription coupling in the nervous system: involvement of the inducible proto-oncogenes fos and jun Annu. Rev. Neurosci. 14 1991 421 451
29. 9-tetrahydrocannabinol and antagonist activity of cannabidiol on rat brain cannabinoid receptors Life Sci. 63 1998 1 6
30. D. Piomelli The molecular logic of endocannabinoid signaling Nat. Rev., Neurosci. 4 2003 873 884
31. J.L. Pretorius, M. Philips, R.W. Langley, E. Szabadi, and C.M. Bradshaw Comparison of clozapine and haloperidol on some autonomic and psychomotor functions, and on serum prolactin concentration, in healthy subjects Br. J. Clin. Pharmacol. 52 2001 322 326
32. W.H. Rifee, and R.E. Wilcox Effects of multiple pre-treatment with apomorphine and amphetamine on amphetamine-induced locomotor activity and its inhibition by apomorphine Psychopharmacology 85 1985 97 101
33. G.S. Robertson, and H.C. Fibiger Neuroleptics increase c-Fos expression in the forebrain: contrasting effects of haloperidol and clozapine Neuroscience 46 1992 315 328
34. G.S. Robertson, M. Matsumura, and H.C. Fibiger Induction patterns of Fos-like immunoreactivity in the forebrain as predictors of atypical antipsychotic activity J. Pharmacol. Exp. Ther. 271 1994 1058 1066
35. D. Rottanburg, A.H. Robins, O. Ben-Aire, A. Teggin, and R. Elk Cannabis-associated psychosis with hypomaniac feature Lancet 2 1982 1364 1366
36. P.R. Sanberg, M.D. Bunsey, M. Giordano, and A.B. Norman The catalepsy test: its ups and downs Behav. Neurosci. 102 1988 748 759
37. P. Seeman Atypical antipsychotic drugs: mechanisms of action Can. J. Psychiatry 47 2002 27 38
38. P.G. Strange Antipsychotic drugs: importance of dopamine receptors for mechanisms of therapeutic actions and side effects Pharmacol. Rev. 53 2001 119 133
39. B.F. Thomas, A.F. Gillian, D.F. Burch, M.J. Roche, and H.H. Seltzman Comparative receptor analyses of cannabinoid agonists and antagonists J. Pharmacol. Exp. Ther. 285 1998 285 292
40. F.X. Vollenweider, and M.A. Geyer A systems model of altered consciousness: integrating natural and drug-induced psychoses Brain Res. Bull. 56 2001 495 507
41. 9-tetrahydrocannabinol and cannabidiol, separately or in combination Braz. J. Med. Biol. Res. 16 1983 141 146
42. 9-THC in normal subjects Psychopharmacology 76 1982 245 250
43. A.W. Zuardi, J. Antunes-Rodrigues, and J.M. Cunha Effects of cannabidiol in animal models predictive of antipsychotic activity Psychopharmacology 104 1991 260 264
44. A.W. Zuardi, S.L. Morais, F.S. Guimarães, and R. Mechoulam Antipsychotic effect of cannabidiol J. Clin. Psychiatry 56 1995 485 486